Disease · MONDO_0005446
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| WR 279,396 vs Paromomycin: deaths from any cause | 0 of 201 | 0 of 198 | 399 | NCT01790659 | Trial comparisons |
| WR 279,396 vs Paromomycin: serious adverse events | 2 of 201 | 1 of 198 | 399 | NCT01790659 | Trial comparisons |
| WR 279,396 vs Placebo: Rate of Relapse | 0 of 50 | 3 of 42 | 92 | NCT00703924 | Trial comparisons |
| WR 279,396 vs Placebo: serious adverse events | 1 of 50 | 0 of 42 | 92 | NCT00703924 | Trial comparisons |
| Sodium Stibogluconate Intravenous vs ThermoMed Device: deaths from any cause | 0 of 28 | 0 of 28 | 56 | NCT00884377 | Trial comparisons |
| Sodium Stibogluconate Intravenous vs ThermoMed Device: serious adverse events | 5 of 28 | 2 of 28 | 56 | NCT00884377 | Trial comparisons |
| WR279,396 With Tegaderm Dressing vs WR279,396 With Gauze and Tape Dressing: deaths from any cause | 0 of 24 | 0 of 24 | 48 | NCT01536795 | Trial comparisons |
| WR279,396 With Tegaderm Dressing vs WR279,396 With Gauze and Tape Dressing: serious adverse events | 0 of 24 | 0 of 24 | 48 | NCT01536795 | Trial comparisons |
| Paromomycin Alone Treatment vs WR 279,396: Final Clinical Cure for Index Lesions | 11 of 16 | 9 of 14 | 30 | NCT01032382 | Trial comparisons |
| Paromomycin Alone Treatment vs WR 279,396: serious adverse events | 0 of 16 | 0 of 14 | 30 | NCT01032382 | Trial comparisons |
| Paromomycin Alone Treatment vs WR 279,396: Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions | 8 of 15 | 13 of 15 | 30 | NCT01083576 | Trial comparisons |
| Paromomycin Alone Treatment vs WR 279,396: Number of Participants Who Obtained Final Clinical Cure of Index Lesion | 9 of 15 | 13 of 15 | 30 | NCT01083576 | Trial comparisons |
| Paromomycin Alone Treatment vs WR 279,396: serious adverse events | 0 of 15 | 0 of 15 | 30 | NCT01083576 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005446/comparisons